Eric Julian Manalastas,Aditi Hombali,Juliette C Thompson et al.
Eric Julian Manalastas et al.
Objectives: Retractions of scientific articles have increased over time, across different health fields, disease indications, and study designs. However, it is currently unknown whether, and to what extent, retractions ha...
Potential Economic Value of Multi-cancer Early Detection Testing Under Differential Cost Trends for Cancer Screening and Management [0.03%]
不同癌症筛查和治疗成本趋势下的多重癌症早期检测的潜在经济价值
Anuraag R Kansal,Ali Tafazzoli,Weicheng Ye et al.
Anuraag R Kansal et al.
Objectives: Multi-cancer early detection (MCED) tests aim to reduce the clinical and economic burden of cancer by detecting cases at earlier, more treatable stages. Recent trends indicate that the costs of cancer manageme...
Budget Impact of the LungFlag™ Predictive Risk Model for Lung Cancer Screening [0.03%]
LungFlag肺部癌症筛查预测模型的影响因素预算分析
Carolina Heuser,Michael K Gould,Eran Choman et al.
Carolina Heuser et al.
Background/objective: Lung cancer screening has historically been associated with false-positive results that can lead to complications and increased costs. LungFlag is a machine-learning risk prediction model using indiv...
Economic Evaluation of NHS England's Type 2 Diabetes Path to Remission Pilot Scheme: Evidence From Real-World Data and Patient Simulation Modelling [0.03%]
基于真实世界数据和患者模拟建模的英格兰全民医疗保健系统第二类糖尿病缓解试点方案的经济评估证据
Adam Martin,Tayamika Zabula,Davide Tebaldi et al.
Adam Martin et al.
Background: The 'Type 2 Diabetes Path to Remission' programme (T2DPR) of NHS England (NHSE) is a low-calorie diet intervention with behavioural support for adults with a recent type 2 diabetes mellitus (T2D) diagnosis and...
Use of Health State Utility Values in Cost-Utility Analyses of Selected Infectious Diseases in Aging Populations: A Systematic Review and Critical Appraisal [0.03%]
老龄化人群中传染病成本效益分析中健康状态效用值的运用：系统综述与批判性评价
Thi Hao Pham,Jovan Mihajlović,Ivan Loncar et al.
Thi Hao Pham et al.
Background: Health state utility values (HSUVs) are vital in cost-utility analyses (CUAs) that inform policymaking. However, suboptimal selection and application of HSUVs have been reported in areas such as cardiovascular...
Cost-Effectiveness of Chimeric Antigen Receptor (CAR) T-Cell Therapy for Blood Cancers: An Updated Systematic Review [0.03%]
嵌合抗原受体T细胞疗法治疗血液系统恶性肿瘤的 cost-effectiveness：一项更新的系统综述
Nishma Patel,Suzanne Farid,Manuel Gomes
Nishma Patel
Background: Chimeric antigen receptor (CAR) T-cell therapy is an area of rapid development, showing the promise of curing blood cancers. While substantial health gains may justify high costs, it is currently unclear the e...
Societal Economic Burden of Antibiotic Resistance in Uganda: A Cost of Illness Study [0.03%]
乌干达抗生素抗药性的社会经济负担：一种疾病负担研究
Elly Nuwamanya,Jonathan Mayito,Stephen Okoboi et al.
Elly Nuwamanya et al.
Background: Antibiotic resistance (ABR), largely owing to inappropriate prescriptions and misuse of antibiotics, threatens the effectiveness of current and future antibiotic treatments, resulting in prolonged hospitalizat...
Global Assessment of Health Utilities Associated with Pneumococcal Disease in Adults: Targeted Literature Reviews [0.03%]
成人肺炎球菌性疾病健康效用全球评估：目标文献回顾
Min Huang,Jipan Xie,Hela Romdhani et al.
Min Huang et al.
Background: Pneumococcal disease can significantly reduce quality of life (QoL). Health utilities are commonly used to assess QoL burden and calculate quality-adjusted life years (QALYs), which are critical inputs in cost...
Impact of Inhibitor Development on the Cost Effectiveness of Prophylactic Treatment with Recombinant Factor VIII in Previously Untreated Patients with Severe Hemophilia A [0.03%]
抑制剂生成对严重甲型血友病患者使用重组VIII因子进行预防性治疗的成本效益的影响分析
Li Yang,Jie Peng,Congling Gu et al.
Li Yang et al.
Background/objectives: Inhibitor development against recombinant factor VIII (rFVIII) is a significant complication in the prophylactic treatment of severe hemophilia A. The economic impact of varying inhibitor risks amon...